Sign up to save your podcasts
Or
Share S2 Ep46: Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S2 Ep46: Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; and Christine M. Lovly, MD, PhD, FASCO, discuss current and emerging treatment strategies targeting HER2 and TROP2 in patients with advanced or metastatic non–small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 2238
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Consultant; Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Janssen, Merck & Co, Novartis, Takeda.
Faculty:
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Atlanta, GA
Disclosures: Adviser/Consultant: AbbVie, Amgen, AstraZeneca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Genentech, Gilead Sciences, Jazz, Johnson & Johnson, Novartis, Novacure, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda; DSMB: OncoC4; Research grant (paid to institution): Bayer, Boehringer Ingelheim, Daiichi Sankyo, Mythic, Prelude, Synthekine.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisory Board/Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi; Employment (Spouse): Boston Scientific; Grant/Research Support: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL Therapeutics; Stock (Spouse): Boston Scientific.
Christine M. Lovly, MD, PhD, FASCO
Associate Professor of Medicine
Division of Hematology-Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Consultant: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus; Honoraria Recipient: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on biomarker testing in NSCLC, and additional information about HER2-targeted and TROP2-targeted therapy, go https://www.gotoper.com/annual-oncology-meeting-25-her2trop2-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
View all episodes
By PER® SpectivesThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; and Christine M. Lovly, MD, PhD, FASCO, discuss current and emerging treatment strategies targeting HER2 and TROP2 in patients with advanced or metastatic non–small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 2238
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Consultant; Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Janssen, Merck & Co, Novartis, Takeda.
Faculty:
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Atlanta, GA
Disclosures: Adviser/Consultant: AbbVie, Amgen, AstraZeneca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Genentech, Gilead Sciences, Jazz, Johnson & Johnson, Novartis, Novacure, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda; DSMB: OncoC4; Research grant (paid to institution): Bayer, Boehringer Ingelheim, Daiichi Sankyo, Mythic, Prelude, Synthekine.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisory Board/Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi; Employment (Spouse): Boston Scientific; Grant/Research Support: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL Therapeutics; Stock (Spouse): Boston Scientific.
Christine M. Lovly, MD, PhD, FASCO
Associate Professor of Medicine
Division of Hematology-Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Consultant: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus; Honoraria Recipient: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on biomarker testing in NSCLC, and additional information about HER2-targeted and TROP2-targeted therapy, go https://www.gotoper.com/annual-oncology-meeting-25-her2trop2-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.